Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital’s experience. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.